CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease

AstraZeneca (AZN) announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the regulatory filing seeking label expansion in the EU for its blockbuster asthma drug Fasenra (benralizumab) in eosinophilic granulomatosis with polyangiitis (EGPA) indication.EGPA is a rare autoimmune disease that can cause damage to multiple organs and tissues. The AZN filing seeks marketing authorization for Fasenra as an add-on treatment for adult patients with relapsing or refractory ...